PeptideCompareHexarelin — EU research guide.
Hexarelin (Examorelin) is a synthetic hexapeptide GH secretagogue and ghrelin receptor agonist. It is the most potent GHS-R1a agonist among the classic GHRP peptides and additionally demonstrates direct cardioprotective effects independent of GH release.
What is Hexarelin?
Hexarelin is a synthetic hexapeptide with a 2-methyltryptophan substitution that confers high affinity for GHS-R1a. It produces the most potent GH pulse of the GHRP class but also causes the most pronounced cortisol and prolactin responses. Its direct cardiac effects — mediated through non-GHS-R mechanisms including CD36 — make it a compound of interest in cardiovascular research beyond its GH effects.
What does the research show?
Human studies confirm potent GH release with desensitisation upon repeated dosing — a characteristic that limits sustained use research. Cardiac research: in rat ischaemia-reperfusion models, hexarelin reduced infarct size and improved contractile function via a GH-independent mechanism (CD36 receptor). The cardioprotective profile is a distinct research angle compared to other GHRPs.
EU legal status
Not approved in the EU. WADA-prohibited (S2). Available for laboratory research only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Hexarelin across EU suppliers
COA-verified EU vendors · Updated monthly
Frequently asked questions
What is Hexarelin? ▾
Hexarelin is a synthetic hexapeptide with a 2-methyltryptophan substitution that confers high affinity for GHS-R1a. It produces the most potent GH pulse of the GHRP class but also the most pronounced cortisol and prolactin responses.
Why is Hexarelin studied in cardiovascular research? ▾
It has direct cardiac effects mediated through non-GHS-R mechanisms including the CD36 receptor, making it of interest beyond its GH effects.
What does the research show? ▾
Human studies confirm potent GH release with desensitisation on repeated dosing, and in rat ischaemia-reperfusion models it reduced infarct size and improved contractile function via a GH-independent CD36 mechanism.
Why does Hexarelin's effect diminish with repeated use? ▾
Human studies show desensitisation upon repeated dosing, a characteristic that limits sustained-use research.
Is Hexarelin legal in the EU? ▾
It is sold as a research compound for laboratory use only.
Is Hexarelin banned in sport? ▾
Yes. It appears on the WADA prohibited list (S2).
References
- Human study comparing the endocrine activity of ghrelin, hexarelin and GHRH. Hexarelin is a GH-releasing peptide (a ghrelin-receptor agonist), a different mechanism from the GHRH analogues above. Arvat E, et al. J Clin Endocrinol Metab. 2001;86(3):1169–1174. DOIPubMed 11238504
- Acute hexarelin given during coronary-artery bypass surgery increased left-ventricular ejection fraction. Most of hexarelin's distinctive interest is cardiovascular rather than the muscle-building framing it is usually sold under. Broglio F, et al. Eur J Pharmacol. 2002;448(2–3):193–200. PubMed 12144941